[go: up one dir, main page]

WO1999066065A3 - Proteasomal activity - Google Patents

Proteasomal activity Download PDF

Info

Publication number
WO1999066065A3
WO1999066065A3 PCT/GB1999/001840 GB9901840W WO9966065A3 WO 1999066065 A3 WO1999066065 A3 WO 1999066065A3 GB 9901840 W GB9901840 W GB 9901840W WO 9966065 A3 WO9966065 A3 WO 9966065A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
assays
identifying
proteasomal
methods
Prior art date
Application number
PCT/GB1999/001840
Other languages
French (fr)
Other versions
WO1999066065A2 (en
Inventor
Hans-Peter Schmid
Franck Petit
Peter-Michael Kloetzel
Anne-Sophie Jarrousse
Karine Gautier
Saloua Badaoui
Said Mouzeyar
Paul Nicolas
Original Assignee
Bridgehead Technologies Limite
Schmid Hans Peter
Franck Petit
Kloetzel Peter Michael
Jarrousse Anne Sophie
Karine Gautier
Saloua Badaoui
Said Mouzeyar
Paul Nicolas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812756.6A external-priority patent/GB9812756D0/en
Priority claimed from GBGB9812759.0A external-priority patent/GB9812759D0/en
Priority claimed from GBGB9812758.2A external-priority patent/GB9812758D0/en
Priority claimed from GBGB9812760.8A external-priority patent/GB9812760D0/en
Priority claimed from GBGB9812757.4A external-priority patent/GB9812757D0/en
Application filed by Bridgehead Technologies Limite, Schmid Hans Peter, Franck Petit, Kloetzel Peter Michael, Jarrousse Anne Sophie, Karine Gautier, Saloua Badaoui, Said Mouzeyar, Paul Nicolas filed Critical Bridgehead Technologies Limite
Priority to JP2000554874A priority Critical patent/JP2002518020A/en
Priority to CA002330210A priority patent/CA2330210A1/en
Priority to EP99957075A priority patent/EP1088100A2/en
Priority to AU42811/99A priority patent/AU4281199A/en
Publication of WO1999066065A2 publication Critical patent/WO1999066065A2/en
Publication of WO1999066065A3 publication Critical patent/WO1999066065A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
    • C12Q2337/20—Coumarin derivatives
    • C12Q2337/22—7-Amino-4-methylcoumarin, i.e. AMC, MCA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to modulation and/or regulation of proteasomal activity. The invention provides assay methods for identifying compounds which inhibit viral replication and pathogenesis, for identifying inhibitors of the nuclease-inhibitory function of the human immunodeficiency virus TAT protein, for identifying inhibitors of the protease-inhibitory function of the human immunodeficiency virus TAT protein, for identifying compounds which change the concentrations of regulatory proteins by modulating the rate of proteasomal destruction of specific mRNAs, and methods for generating resistance to bacterial or viral infection damage. The invention provides assays, kits for carrying out said assays, compounds identified by said assays, together with amino acid sequences encoding said compounds and medicinal compositions derived therefrom. Where legally permissible the invention also provides methods of treatment based on the modulation/regulation of proteasomal activity.
PCT/GB1999/001840 1998-06-13 1999-06-10 Proteasomal activity WO1999066065A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000554874A JP2002518020A (en) 1998-06-13 1999-06-10 Proteasome activity
CA002330210A CA2330210A1 (en) 1998-06-13 1999-06-10 Proteasomal activity
EP99957075A EP1088100A2 (en) 1998-06-13 1999-06-10 Proteasomal activity
AU42811/99A AU4281199A (en) 1998-06-13 1999-06-10 Proteasomal activity

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB9812758.2 1998-06-13
GB9812757.4 1998-06-13
GBGB9812756.6A GB9812756D0 (en) 1998-06-13 1998-06-13 Assay procedure for identifying inhibitors of the nuclease-inhibitory function of the human immunodeficiency virus tat protein
GBGB9812759.0A GB9812759D0 (en) 1998-06-13 1998-06-13 A procedure for generating resistance to bacterial or viral infection damage
GBGB9812758.2A GB9812758D0 (en) 1998-06-13 1998-06-13 Proteasomal destruction of mRNA
GB9812756.6 1998-06-13
GBGB9812760.8A GB9812760D0 (en) 1998-06-13 1998-06-13 A method for identifying compounds which inhibit viral replication and pathogenesis
GB9812759.0 1998-06-13
GBGB9812757.4A GB9812757D0 (en) 1998-06-13 1998-06-13 Assay procedure for identifying inhibitors of the protease-inhibitory function of the human immunodeficiency virus tat protein
GB9812760.8 1998-06-13

Publications (2)

Publication Number Publication Date
WO1999066065A2 WO1999066065A2 (en) 1999-12-23
WO1999066065A3 true WO1999066065A3 (en) 2000-04-20

Family

ID=27517463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001840 WO1999066065A2 (en) 1998-06-13 1999-06-10 Proteasomal activity

Country Status (5)

Country Link
EP (1) EP1088100A2 (en)
JP (1) JP2002518020A (en)
AU (1) AU4281199A (en)
CA (1) CA2330210A1 (en)
WO (1) WO1999066065A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914648A (en) * 1998-10-20 2001-11-27 Millennium Pharm Inc Process to monitor drug action of proteasome inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029244A1 (en) * 1994-04-26 1995-11-02 Wisconsin Alumni Research Foundation Method to increase regulatory molecule production
WO1997025618A1 (en) * 1996-01-05 1997-07-17 Icos Corporation Cytoplasmic modulators of integrin binding/signalling
WO1998036070A1 (en) * 1997-02-18 1998-08-20 Signal Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-λB ACTIVATION
EP0943624A1 (en) * 1998-03-12 1999-09-22 Universiteit Utrecht Peptidic inhibitors of down-regulation of growth hormone receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029244A1 (en) * 1994-04-26 1995-11-02 Wisconsin Alumni Research Foundation Method to increase regulatory molecule production
WO1997025618A1 (en) * 1996-01-05 1997-07-17 Icos Corporation Cytoplasmic modulators of integrin binding/signalling
WO1998036070A1 (en) * 1997-02-18 1998-08-20 Signal Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-λB ACTIVATION
EP0943624A1 (en) * 1998-03-12 1999-09-22 Universiteit Utrecht Peptidic inhibitors of down-regulation of growth hormone receptor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ADAMS J ET AL: "CHAPTER 28. NOVEL INHIBITORS OF THE PROTEASOME AND THEIR THERAPEUTIC USE IN INFLAMMATION", ANNUAL REPORTS IN MEDICINAL CHEMISTRY,US,SAN DIEGO, pages 279-288, XP000791150, ISSN: 0065-7743 *
DATABASE SWISSPROT 1 August 1992 (1992-08-01), DEMARTINO, G.N. ET AL.: "Multicatalytic endopeptidase complex zeta chain." *
DEMARTINO, G.N.: "The primary structures of four subunits of the human, high molecular weight proteinase, macropain (proteasome), are distinct but homologous.", BIOCHEM. BIOPHYS. ACTA, vol. 1079, 1991, pages 29 - 38, XP000865674 *
LEVITSKAYA, J. ET AL.: "Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear Antigen", PROCEEDINGS OF THE NATIONAL ACADAMY OF SCIENCES USA, vol. 94, November 1997 (1997-11-01), pages 12616 - 12621, XP002126609 *
PETIT, F. ET AL.: "Involvement of proteasomal suunits zeta en iota in RNA degradation", BIOCHEM. J., vol. 326, 1997, pages 93 - 98, XP000865614 *
PETIT, F. ET AL.: "Proteasome (prosome) associated endonuclease activity", MOLECULAR BIOLOGY REPORTS, vol. 24, no. 1-2, March 1997 (1997-03-01), pages 113 - 117, XP002126606 *
POUCH, M-N. ET AL.: "Identification and initial characterisation of a specific proteasome(prosome) associated RNase activity", THE JOURNAL FO BIOLOGICAL CHEMISTRY, vol. 270, no. 37, 1995, pages 22023 - 22028, XP002126608 *
SCHUBERT, U. ET AL.: "CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugation pathway", JOURNAL OF VIROLOGY, vol. 72, no. 3, March 1998 (1998-03-01), pages 2280 - 2288, XP002121469 *
SCHWARTZ, O. ET AL.: "Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1", JOURNAL OF VIROLOGY, vol. 72, no. 5, May 1998 (1998-05-01), pages 3845 - 3850, XP002121467 *

Also Published As

Publication number Publication date
WO1999066065A2 (en) 1999-12-23
AU4281199A (en) 2000-01-05
CA2330210A1 (en) 1999-12-23
EP1088100A2 (en) 2001-04-04
JP2002518020A (en) 2002-06-25

Similar Documents

Publication Publication Date Title
ATE231496T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
ATE373093T1 (en) SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS MEDICINAL PRODUCTS AND DIAGNOSTICS
PT813542E (en) RETROVIRAL PROTEASE INHIBITORS HYDROXYETHYLAMINO SULFONAMOD AMINO ACID
BR9814276A (en) Surface antigens
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
NO974149D0 (en) Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
DE69504383D1 (en) Bisulfite addition compounds of arginine aldehydes and their use as thrombin inhibitors and anticoagulants
DE69802389D1 (en) CONNECTIONS USED AS EFFECTORS OF NEUROEXCITATORY AMINO ACID SENSITIVE RECEPTORS OF THE CENTRAL VENEER SYSTEM, THEIR PRODUCTION AND THEIR BIOLOGICAL USE
BR9910573A (en) Antipicornoviral compounds, preparation and use thereof
DK0662948T3 (en) 2-Amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and / or kynurenine-3-hydroxylase inhibitory effect
WO2004085682A3 (en) Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza
WO2000034511A3 (en) Aβ-PEPTIDE SCREENING ASSAY
DE69631158D1 (en) COMPOUNDS AND THEIR USE FOR TREATING INFECTIOUS DISEASES
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
DE69614824D1 (en) METHOD FOR THE PRODUCTION OF INTERMEDIATE PRODUCTS INHIBITING RETROVIAL PROTEASE
ATE361359T1 (en) FUNCTION AND ACTIVITY OF VIRAL PROTEIN R (VPR)
ATE296607T1 (en) PREPARATION FOR REMOVAL OF ABNORMAL KERATIN MATERIAL
DK0840792T3 (en) (S) hydroxynitrilase from Hevea brasiliensis
WO1999066065A3 (en) Proteasomal activity
DK0833848T3 (en) Factor IX binding peptides derived from factor VIII and its use as inhibitors of blood coagulation
DK0852623T3 (en) Nucleic acid molecules encoding proteins that mediate the adhesion of Neisseria cells to human cells
ATE312179T1 (en) AGENT CONTAINING SERINE-THREONINE KINASE FOR TUMOR THERAPY AND TUMOR DIAGNOSIS
ATE390440T1 (en) NEUROACTIVE PEPTIDES
DE69934098D1 (en) NEW DIAGNOSTIC REAGENT AND KIT FOR DETECTING RICKETTESIS
BR0007499A (en) Compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999957075

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2330210

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 42811/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000/07445

Country of ref document: ZA

Ref document number: 200007445

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1999957075

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09719171

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999957075

Country of ref document: EP